Fraunhofer ITEM

Fraunhofer ITEM aims to protect man from health hazards in our industrialized world and to contribute to the development of novel therapeutic approaches. Focusing on lung and inhalation, Fraunhofer ITEM has pooled its expertise in three business units: In the business unit Drug Development, we develop and test novel medications against respiratory diseases. Scientific expertise covers manufacturing of biologics, preclinical and clinical development. The business unit Chemical Safety is dedicated to determining the risks from potentially harmful substances. Scientific expertise includes toxicology testing, exposure assessment, analytical methods, regulatory research and risk assessment. The business unit Translational Biomedical Engineering offers many...

Toxicology testing,pre-clinical pharmacology,early-phase clinical trials,registration and risk assessment,environmental,occupational and consumer protection,manufacturing of biopharmaceuticals,translational biomedical engineering,personalized tumor-therapy,exposure characterization,cardiovascular research ,and rna-research

Fraunhofer item operates in the Research services industry.

Fraunhofer item's revenue is 11m - 100m

Fraunhofer item has 201 - 500 employees.